We’ve seen tremendous progress in the field of cancer immunotherapy in recent years, and the potential now exists to improve on the benefits obtained with monotherapy by combining agents with complementary mechanisms of action.
More than 800 trials of immune-based combination therapies are underway; coupled with increasing opportunities for collaboration between the pharmaceutical and biotech industries, government and academia, the field is at an exciting juncture where the potential for novel therapeutic approaches has never been greater.
The Society for Immunotherapy of Cancer (SITC) Combination Immunotherapies Task Force has convened to:
The Combination Immunotherapies Task Force focus is upon the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer. Standardization of assays, assay validation, and appropriate potency assays were the subjects of one subcommittee while the other assessed the clinical utility of promising novel technologies and made recommendations on how to incorporate these into the clinical arena.
Patrick Ott, MD, PhD Dana-Farber Cancer Institute/Harvard Medical School
[Holbrook E. Kohrt, MD, PhD*] Stanford Cancer Institute
F. Stephen Hodi, MD Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACSReplimune Group Inc.
Jon M. Wigginton, MD MacroGenics, Inc.
Jedd D. Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center
*Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016) Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC.
Journal for ImmunoTherapy of Cancer, February 2017
By summarizing the current status of combination immunotherapy, and addressing potential challenges in development and clinical implementation of combinatorial approaches, this paper provides evidence-based guidance to drive progress and improve on the clinical benefits obtained with single therapeutic agents. With greater understanding of the mechanisms of action of immunotherapy agents, and of the counter-defenses mounted by tumors, there is potential for novel combinations to increase the number of patients who respond to immunotherapy, the tolerability of treatment, and the duration of treatment response.
For those of you in the Philadelphia area, CAR-T and The Rise of the Cellicon Valley Thursday, May 9 and Friday, May 10, 2019 World experts in CAR T-cellular therapy and hematopoietic stem cell transplantation (HSCT) have been assembled to ...
This message was posted by a user wishing to remain anonymous The 8th Conference of IAOC "Current Status and Future of Anti-Cancer Therapies" will be held in Buenos Aires, Argentina in October 17th and 18th, 2019. An outstanding faculty of speakers ...
Clinical Application of CAR T Cells
March 14-15, 2019 | New York, NY REGISTER NOW! Space is limited and this course will likely sell out. Current registrants include attendees from over 30 companies and 50 academic institutions . Register ...
Hello Anyone can share their experience with sarcoidosis flare after treatment with a PD-1 inhibitor? Thank you ------------------------------ Priscila Goncalves Associate Director Center for Novel Cancer Therapies Northwell Health - Monter Cancer Center ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com